GMED vs JNJ: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: GMED is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. GMED and JNJ share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined GMED and JNJ exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Globus Medical designs and sells musculoskeletal implants and the enabling technology used to place them. The core business is spine: pedicle screws, interbody cages, cervical plates, expandable implants and the disposable instruments that go with them, sold to hospitals and surgery centers largely through a direct sales force. Sitting on top of that is the enabling-technology line, principally the ExcelsiusGPS robotic navigation platform, the Excelsius3D imaging system and the Excelsius Flex robot aimed at knee replacement. The robots themselves are a modest share of revenue; their commercial purpose is to place capital in a hospital and pull recurring implant volume through it for years afterward. The September 2023 all-stock merger with NuVasive roughly doubled the company's size and made it the second largest spine business in the world behind Medtronic, and the April 2025 acquisition of Nevro added spinal cord stimulation for chronic pain, extending Globus beyond surgical implants into neuromodulation.

Full GMED guide

Johnson & Johnson is one of the world's largest healthcare companies, now focused on two core areas after spinning off its consumer-health business (Kenvue). Its Innovative Medicine segment develops and sells branded prescription drugs across oncology, immunology, neuroscience, cardiovascular, and other areas, with major franchises that drive much of its profit. Its MedTech segment makes medical devices and surgical equipment for cardiovascular intervention, orthopedics, surgery, and vision care. J&J makes money by researching, manufacturing, and selling patented pharmaceuticals and devices to hospitals, physicians, pharmacies, and patients worldwide, supported by one of the largest research and development budgets in healthcare. The company is known for its diversification, financial strength, AAA-class balance sheet, and a multi-decade record of raising its dividend, making it a classic defensive blue chip. Founded in 1886 and headquartered in New Brunswick, New Jersey, J&J is a broadly held, large-cap healthcare company valued for stability, income, and a deep drug and device pipeline.

Full JNJ guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• GMED drivers: NuVasive integration and operating leverage; Robotics as an implant channel.
• JNJ drivers: Innovative Medicine pipeline; MedTech innovation and recovery.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The largest structural risk is pricing: spinal implants face steady per-unit price erosion from hospital purchasing groups and payers, so Globus has to grow procedure volume just to hold revenue flat. For JNJ, j&J faces patent expirations on key drugs, including the eventual loss of exclusivity for major franchises, which requires the pipeline to continually replace lost revenue.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick GMED if you believe its drivers more; JNJ if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the GMED and JNJ guides.

GMED. At roughly $85.90 a share against guided non-GAAP EPS of about $5.00, Globus trades near 17 times forward non-GAAP earnings and roughly 3.7 times trailing revenue, a discount to large-cap medtech peers that typically carry higher multiples. The gap reflects the market pricing spine as a low-growth, price-eroding category and discounting the durability of the current margin expansion. Note that the GAAP and non-GAAP figures diverge widely because merger amortization and integration costs are excluded from the adjusted numbers, so the GAAP earnings multiple is considerably higher.

JNJ. J&J trades at a valuation typical of a large, defensive healthcare blue chip: a moderate multiple reflecting steady low-to-mid single-digit growth, high margins, and very strong cash generation, plus a discount for litigation and patent-cliff overhangs. The market values its diversification, balance-sheet strength, and long dividend record, pricing it as a stable income-and-quality holding rather than a growth stock.

Headline figures (approximate, August 2026): GMED shows revenue (ttm) ~$3.14 billion, q2 2026 revenue ~$789.6 million, up ~6% year over year (~9% excluding Nevro), q2 2026 eps ~$1.10 GAAP, ~$1.34 non-GAAP (non-GAAP up ~56% year over year), adjusted ebitda margin (q2 2026) ~35.4%, expanded ~740 basis points year over year; JNJ shows revenue (ttm) ~$90 billion, operating margin ~25%, net income (ttm) ~$15 billion, p/e (ttm) ~16x.

GMED and JNJ are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined GMED and JNJ exposure against your real portfolio. It is not an investment adviser.